Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2017

01-08-2017 | Research Article

BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines

Authors: M. Cuadros, V. Sánchez-Martín, A. Herrera, C. Baliñas, J. Martín-Padrón, L. Boyero, P. Peinado, P. P. Medina

Published in: Clinical and Translational Oncology | Issue 8/2017

Login to get access

Abstract

Introduction/purpose

BRG1 is a key regulator of leukemia stem cells. Indeed, it has been observed that this type of cells is unable to divide, survive and develop new tumors when BRG1 is down-regulated.

Materials and methods

We assessed BRG1 and miR-155 expression in 23 leukemia cell lines, and two no pathological lymphocyte samples using qPCR. MiR-155 transfection and western blot were used to analyze the relationship between miR-155 and its validated target, BRG1, by measuring protein expression levels. The effect of miR-155 on cell proliferation and prednisolone sensitivity were studied with resazurin assay.

Results

BRG1 expression levels could correlate negatively with miR-155 expression levels, at least in Burkitt’s lymphoma and diffuse large B cell lymphoma (DLBCL) cell lines. To clarify the role of miR-155 in the regulation of BRG1 expression, we administrated miR-155 mimics in different leukemia/lymphoma cell lines. Our results suggest that miR-155 regulate negatively and significantly the BRG1 expression at least in the MOLT4 cell line.

Conclusion

Our study revealed a previously unknown miR-155 heterogeneity that could result in differences in the treatment with miRNAs in our attempt to inhibit BRG1. However, the expression levels of BRG1 and miR-155, before prednisolone treatment were not statistically significantly associated prednisolone sensitive leukemia cells.
Literature
1.
Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11:481–92.CrossRef
2.
Sentani K, Oue N, Kondo H, Kuraoka K, Motoshita J, Ito R, et al. Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas. Pathobiology. 2001;69:315–20.CrossRef
3.
Al Sun, Tawfik O, Gayed B, Thrasher JB, Hoestje S, Li C, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate. 2007;67:203–13.CrossRef
4.
Lin Hl, Wong RP, Martinka M, Li G. BRG1 expression is increased in human cutaneous melanoma. Br J Dermatol. 2010;163:502–10.CrossRef
5.
Song S, Walter V, Karaca M, Li Y, Bartlett CS, Smiraglia DJ, et al. Gene silencing associated with SWI/SNF complex loss during NSCLC development. Mol Cancer Res. 2014;12:560–70.CrossRef
6.
Buscarlet Manuel, Krasteva Veneta, Ho Lena, Simon Camille, Hébert Josée, Wilhelm Brian, et al. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood. 2014;123:1720–8.CrossRef
7.
Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe J, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated MYC regulation. Genes Dev. 2013;27:2648–62.CrossRef
8.
Pottier N, Yang W, Assem M, Panetta JC, Pei D, Paugh SW, et al. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst. 2008;100:1792–803.CrossRef
9.
Rajewsky N. microRNA target predictions in animals. Nat Genet. 2006;38(Suppl):S8–13.CrossRef
10.
Takada S, Yamashita Y, Berezikov E, Hatanaka H, Fujiwara S, Kurashina K, et al. MicroRNA expression profiles of human leukemias. Leukemia. 2008;22:1274–8.CrossRef
11.
Dunand-Sauthier I, Santiago-Raber ML, Capponi L, Vejnar CE, Schaad O, Irla M, et al. Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function. Blood. 2011;117:4490–500.CrossRef
12.
Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316:608–11.CrossRef
13.
Thai TH, Calado DP, Casola S, Ansel KM, Xiao C. Xue Yet al. Regulation of the germinal center response by microRNA-155. Science. 2007;316:604–8.CrossRef
14.
Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005;102:3627–32.CrossRef
15.
Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207:243–9.CrossRef
16.
Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45:592–601.CrossRef
17.
Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, et al. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov. 2014;4:292–303.CrossRef
18.
Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, Sanchez-Cespedes M. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat. 2008;29(5):617–22. doi:10.​1002/​humu.​20730.CrossRefPubMed
19.
Medina PP, Sanchez-Cespedes M. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics. 2008;3(2):64–8.CrossRef
20.
Medina PP, Carretero J, Ballestar E, Angulo B, Lopez-Rios F, Esteller M, Sanchez-Cespedes M. Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. Hum Mol Genet. 2005;14(7):973–82.CrossRef
21.
Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer. 2004;41(2):170–7.CrossRef
22.
Vangamudi B, Paul TA, Shah PK, Kost-Alimova M, Nottebaum L, Shi X, et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res. 2015;75:3865–78.CrossRef
23.
Schiaffino-Ortega S, Balinas C, Cuadros M, Medina PP. SWI/SNF proteins as targets in cancer therapy. J Hematol Oncol. 2014;7:81.CrossRef
24.
Coira IF, Rufino-Palomares EE, Romero OA, Peinado P, Metheetrairut C, Boyero-Corral L, et al. Expression inactivation of SMARCA4by microRNAs in lung tumors. Hum Mol Genet. 2015;24:1400–9.CrossRef
25.
Salemi D, Cammarata G, Agueli C, Augugliaro L, Corrado C, Bica MG, et al. miR-155 regulative network in FLT3 mutated acute myeloid leukemia. Leuk Res. 2015;39:883–96.CrossRef
26.
Ruffin N, Lévy Y, Swaminathan S. Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology. 2014;142:32–8.CrossRef
27.
Den Boer ML. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia. 2012;26:1–12.CrossRef
28.
Gerloff D, Grundler R, Wurm AA, Bräuer-Hartmann D, Katzerke C, Hartmann JU, et al. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia. 2015;3:535–47.CrossRef
29.
Wang M, Tan LP, Dijkstra MK, van Lom K, Robertus JL, Harms G, et al. miRNA analysis in B cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol. 2008;215:13–20.CrossRef
Metadata
Title
BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines
Authors
M. Cuadros
V. Sánchez-Martín
A. Herrera
C. Baliñas
J. Martín-Padrón
L. Boyero
P. Peinado
P. P. Medina
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1633-2

Other articles of this Issue 8/2017

Clinical and Translational Oncology 8/2017 Go to the issue

Research Article

Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study

Research Article

SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors

Research Article

The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis

Review Article

The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review

Research Article

Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis

Research Article

Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits